Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023 - Seite 2

“The research presented at ACR this week further supports the importance of a LUPKYNIS-based treatment regimen to help preserve kidney function in LN patients by producing earlier and greater reductions in proteinuria while allowing patients to maintain stable renal function. We are proud of our sustained research in autoimmune diseases like lupus and remain committed to helping improve kidney health for people living with lupus nephritis,” said Dr. Greg Keenan, Chief Medical Officer of Aurinia.

To characterize the long-term renal impact of LUPKYNIS at the histologic level, researchers analyzed repeat kidney biopsies from a subset of patients in AURORA 2, including 16 patients in the active treatment arm who received LUPKYNIS in combination with MMF and low-dose glucocorticoids and 10 patients in the control arm treated with MMF and low-dose glucocorticoids alone. Histologic changes from baseline to approximately 18 months post-treatment were assessed. Across both study arms, activity scores, which measured active inflammation in LN, improved to a similar degree, while the chronicity scores, a measure of irreversible kidney injury, remained stable. These results confirmed the safety profile of LUPKYNIS showing no associated chronic injury with use. Importantly, patients treated with LUPKYNIS in the overall AURORA 2 cohort maintained stable renal function over the last two years of the study, as measured by eGFR slope analysis, and experienced numerically greater mean reductions in UPCR, compared to patients in the control arm. These results were also recently presented at the annual American Society of Nephrology Kidney Week 2023.

In a subset analysis of three years of data from the AURORA Clinical Program, 44.4% of Black patients treated with LUPKYNIS experienced an improvement in complete renal response at 36 months (n=18) compared to 14.3% of Black patients who achieved complete renal response when treated with MMF and glucocorticoids alone (n= 7 OR: 4.17 (Ci; 0.41, >9.99), p=0.22). These findings among Black patients, a population that often experiences worse outcomes and lower responses to LN treatment, are consistent with the treatment response seen across all racial and ethnic groups treated with LUPKYNIS in the AURORA Clinical Program. These results were also recently presented at the annual American Society of Nephrology Kidney Week 2023.